$77.01−1.28 (−1.63%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Lemaitre Vascular (LMAT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~12.8%/yr (FY21→FY25), net margin 23.1%, and free cash flow (~$74.5M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+6.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲13.5%
249.6
FY21→FY25CAGR +12.8%/yr
Net income ($M)▲31.1%
57.7
FY21→FY25CAGR +21.0%/yr
Free cash flow ($M)▲100.4%
74.5
FY21→FY25CAGR +25.3%/yr
Diluted EPS▲30.6%
2.52
FY21→FY25CAGR +19.2%/yr
What the receipts whisper · what a headline number hides
Share count
+6.8%
21.5mn → 22.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$6.8M
steady at 2.7% of revenue (−2.6% YoY).
Returns vs FCF
27%
$19.9M returned vs $74.5M of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
23¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 65.7% → 71.5%. Net margin 23.1% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 269,356.0 | 249,602.0 | 219,863.0 | 193,484.0 | 161,651.0 | 154,424.0 | ▲13.5% | +12.8% |
Cost of revenue | 75,301.0 | 71,063.0 | 68,962.0 | 66,435.0 | 56,755.0 | 53,042.0 | ▲3.0% | +7.6% |
Gross profit | 194,055.0 | 178,539.0 | 150,901.0 | 127,049.0 | 104,896.0 | 101,382.0 | ▲18.3% | +15.2% |
Research & development | 16,861.0 | 14,139.0 | 15,650.0 | 16,966.0 | 13,294.0 | 11,801.0 | ▼9.7% | +4.6% |
Selling, general & admin | 45,630.0 | 42,024.0 | 36,258.0 | 31,832.0 | 28,745.0 | 25,501.0 | ▲15.9% | +13.3% |
Total operating expenses | 119,354.0 | 110,627.0 | 98,645.0 | 90,337.0 | 78,067.0 | 64,957.0 | ▲12.1% | +14.2% |
Operating incomefeeds ROC rank | 74,701.0 | 67,912.0 | 52,256.0 | 36,712.0 | 26,829.0 | 36,425.0 | ▲30.0% | +16.9% |
Other income, net | 7,134.0 | 7,272.0 | 4,619.0 | 2,763.0 | 661.0 | −2,138.0 | — | — |
Pretax income | 81,835.0 | 75,184.0 | 56,875.0 | 39,475.0 | 27,490.0 | 34,287.0 | ▲32.2% | +21.7% |
Income tax | 18,500.0 | 17,450.0 | 12,837.0 | 9,370.0 | 6,854.0 | 7,380.0 | ▲35.9% | +24.0% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 63,335.0 | 57,734.0 | 44,038.0 | 30,105.0 | 20,636.0 | 26,907.0 | ▲31.1% | +21.0% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.76 | 2.52 | 1.93 | 1.34 | 0.93 | 1.25 | ▲30.6% | +19.2% |
Diluted shares (mn) | 23.07 | 22.93 | 22.78 | 22.42 | 22.17 | 21.48 | ▲0.7% | +1.7% |
| Margins | ||||||||
Gross margin62nd pct in Healthcare | 72.0% | 71.5% | 68.6% | 65.7% | 64.9% | 65.7% | ▲2.9pp | +5.9pp |
Operating margin | 27.7% | 27.2% | 23.8% | 19.0% | 16.6% | 23.6% | ▲3.4pp | +3.6pp |
Net margin88th pct in Healthcare | 23.5% | 23.1% | 20.0% | 15.6% | 12.8% | 17.4% | ▲3.1pp | +5.7pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Lemaitre Vascular's revenue last fiscal year?
Lemaitre Vascular reported revenue of $249.6M in fiscal 2025, up 13.5% from fiscal 2024.
What was Lemaitre Vascular's net income?
Lemaitre Vascular reported net income of $57.7M in fiscal 2025, a net margin of 23.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

